707 related articles for article (PubMed ID: 27029704)
21. Quality of life with palbociclib plus fulvestrant
Tibau A; Martínez MT; Ramos M; De La Cruz-Merino L; Santaballa A; O'Connor M; Martínez-Jañez N; Moreno F; Fernández I; Virizuela JA; Alarcón J; de La Haba-Rodríguez J; Sánchez-Rovira P; Albacar CR; Bueno Muiño C; Kelly C; Casas M; Bezares S; Rosell L; Albanell J
Ther Adv Med Oncol; 2023; 15():17588359221148921. PubMed ID: 36743520
[TBL] [Abstract][Full Text] [Related]
22. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
Mayer EL; DeMichele A; Rugo HS; Miller K; Waks AG; Come SE; Mulvey T; Jeselsohn R; Overmoyer B; Guo H; Barry WT; Huang Bartlett C; Koehler M; Winer EP; Burstein HJ
Ann Oncol; 2019 Sep; 30(9):1514-1520. PubMed ID: 31250880
[TBL] [Abstract][Full Text] [Related]
23. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
24. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
25. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
Turner NC; Liu Y; Zhu Z; Loi S; Colleoni M; Loibl S; DeMichele A; Harbeck N; André F; Bayar MA; Michiels S; Zhang Z; Giorgetti C; Arnedos M; Huang Bartlett C; Cristofanilli M
J Clin Oncol; 2019 May; 37(14):1169-1178. PubMed ID: 30807234
[TBL] [Abstract][Full Text] [Related]
26. Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Pritchard KI; Chia SK; Simmons C; McLeod D; Paterson A; Provencher L; Rayson D
Oncologist; 2017 Jan; 22(1):12-24. PubMed ID: 27864574
[TBL] [Abstract][Full Text] [Related]
27. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
Ettl J; Im SA; Ro J; Masuda N; Colleoni M; Schnell P; Bananis E; Lu DR; Cristofanilli M; Rugo HS; Finn RS
Breast Cancer Res; 2020 Mar; 22(1):27. PubMed ID: 32164785
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Gelmon KA; Cristofanilli M; Rugo HS; DeMichele AM; Joy AA; Castrellon A; Sleckman B; Mori A; Theall KP; Lu DR; Huang X; Bananis E; Finn RS; Slamon DJ
Breast J; 2020 Mar; 26(3):368-375. PubMed ID: 31448513
[TBL] [Abstract][Full Text] [Related]
29. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Diéras V; Rugo HS; Schnell P; Gelmon K; Cristofanilli M; Loi S; Colleoni M; Lu DR; Mori A; Gauthier E; Huang Bartlett C; Slamon DJ; Turner NC; Finn RS
J Natl Cancer Inst; 2019 Apr; 111(4):419-430. PubMed ID: 30032196
[TBL] [Abstract][Full Text] [Related]
30. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
31. Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.
Fasching PA; Beck JT; Chan A; De Laurentiis M; Esteva FJ; Jerusalem G; Neven P; Pivot X; Bianchi GV; Martin M; Chandiwana D; Lanoue B; Ridolfi A; Wang Y; Rodriguez Lorenc K; Nusch A
Breast; 2020 Dec; 54():148-154. PubMed ID: 33065342
[TBL] [Abstract][Full Text] [Related]
32. Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPE
García-Sáenz JA; Marmé F; Untch M; Bonnefoi H; Kim SB; Bear H; Mc Carthy N; Gelmon K; Martin M; Kelly CM; Reimer T; Toi M; Law E; Bhattacharyya H; Gnant M; Makris A; Seiler S; Burchardi N; Nekljudova V; Loibl S; Rugo HS
Eur J Cancer; 2024 Jan; 196():113420. PubMed ID: 38000218
[TBL] [Abstract][Full Text] [Related]
33. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
Martin M; Zielinski C; Ruiz-Borrego M; Carrasco E; Turner N; Ciruelos EM; Muñoz M; Bermejo B; Margeli M; Anton A; Kahan Z; Csöszi T; Casas MI; Murillo L; Morales S; Alba E; Gal-Yam E; Guerrero-Zotano A; Calvo L; de la Haba-Rodriguez J; Ramos M; Alvarez I; Garcia-Palomo A; Huang Bartlett C; Koehler M; Caballero R; Corsaro M; Huang X; Garcia-Sáenz JA; Chacón JI; Swift C; Thallinger C; Gil-Gil M
Ann Oncol; 2021 Apr; 32(4):488-499. PubMed ID: 33385521
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
Darrigues L; Pierga JY; Bernard-Tessier A; Bièche I; Silveira AB; Michel M; Loirat D; Cottu P; Cabel L; Dubot C; Geiss R; Ricci F; Vincent-Salomon A; Proudhon C; Bidard FC
Breast Cancer Res; 2021 Mar; 23(1):31. PubMed ID: 33676547
[TBL] [Abstract][Full Text] [Related]
35. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
[TBL] [Abstract][Full Text] [Related]
36. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Fribbens C; O'Leary B; Kilburn L; Hrebien S; Garcia-Murillas I; Beaney M; Cristofanilli M; Andre F; Loi S; Loibl S; Jiang J; Bartlett CH; Koehler M; Dowsett M; Bliss JM; Johnston SR; Turner NC
J Clin Oncol; 2016 Sep; 34(25):2961-8. PubMed ID: 27269946
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment.
Dhakal A; Matthews CM; Levine EG; Salerno KE; Zhang F; Takabe K; Early AP; Edge SB; O'Connor T; Khoury T; Young JS; Opyrchal M
Clin Breast Cancer; 2018 Dec; 18(6):e1401-e1405. PubMed ID: 29778787
[TBL] [Abstract][Full Text] [Related]
38. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
Rugo HS; Finn RS; Diéras V; Ettl J; Lipatov O; Joy AA; Harbeck N; Castrellon A; Iyer S; Lu DR; Mori A; Gauthier ER; Bartlett CH; Gelmon KA; Slamon DJ
Breast Cancer Res Treat; 2019 Apr; 174(3):719-729. PubMed ID: 30632023
[TBL] [Abstract][Full Text] [Related]
39. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
Rugo HS; Cristofanilli M; Loibl S; Harbeck N; DeMichele A; Iwata H; Park YH; Brufsky A; Theall KP; Huang X; McRoy L; Bananis E; Turner NC
Oncologist; 2021 Aug; 26(8):e1339-e1346. PubMed ID: 34037282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
